What is PCOD? Meaning and full form
PCOD stands for polycystic ovarian disease, and the easiest way to hold on to it is what we call "one condition, three names": PCOD was an earlier name for the condition that authorities later settled on calling PCOS, and in 2026 PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS.
In plain words, the WHO describes it as a common hormonal condition in which higher than normal androgen levels can lead to irregular periods, problems with ovulation, extra facial or body hair, acne and infertility. Androgens include testosterone, and the condition affects women during their reproductive years and beyond.
The full form explains where the name came from
Writing in an Indian endocrinology journal in 2013, Kalra and colleagues described polycystic ovarian disease (PCOD) as the condition's second name, after "Stein Leventhal syndrome", and Stein and Leventhal first described the problem in 1935.
Are PCOD and PCOS the same?
Yes: in medical writing PCOD and PCOS refer to one condition, and PCOS is the name that authorities including the NIH chose after PCOD.
Indian research still uses both words side by side: a 2014 Mumbai study opens by calling it "polycystic ovary disease", and the same study then measured it using PCOS criteria.
The "two different diseases" idea has no guideline behind it
You may read online that PCOD is a separate, milder problem, yet the WHO fact sheet and the 2023 International Evidence-based Guideline both describe a single condition named PCOS, and neither sets out PCOD as a separate diagnosis.
What varies is the mix of features: a 2024 national Indian study found two combinations, called phenotypes C and D, were the most common, and the Mumbai study called infrequent periods with polycystic-looking ovaries "mild PCOS".
Table 1. PCOD, PCOS and PMOS at a glance
| Name | Full form | What the source says |
|---|---|---|
| PCOD | Polycystic ovarian disease | An earlier name for the condition, before PCOS (Kalra et al., 2013) |
| PCOS | Polycystic ovary syndrome | The name used by the WHO fact sheet and the 2023 International Guideline |
| PMOS | Polyendocrine metabolic ovarian syndrome | The consensus new name for PCOS, published in The Lancet in 2026 |
Source: Kalra et al., Indian J Endocrinol Metab, 2013; WHO PCOS fact sheet, 2026; Teede et al., Hum Reprod, 2023; Teede et al., The Lancet, 2026.
Why has PCOS been renamed PMOS?
In 2026, an international consensus published in The Lancet chose polyendocrine metabolic ovarian syndrome (PMOS) as the new name for PCOS. The authors found the old name inaccurate because it implies pathological ovarian cysts, hides the condition's endocrine and metabolic features, and adds to delayed diagnosis and stigma.
The process engaged 56 academic, clinical and patient organisations and gathered survey responses from 14,360 people with PCOS and health professionals from all world regions. The new name drops the word "cysts" and instead names endocrine, metabolic and ovarian dysfunction.
People with PCOS asked for the change
What the new name means for you
PMOS is the same condition previously named PCOS, which affects one in eight women. A transition period, education and alignment with health systems and disease classification are under way, so you may see PCOD, PCOS and PMOS used side by side for some time.
Why does PCOD happen?
Hormone signals work differently
The WHO explains that PCOS occurs when inappropriate hormonal signalling leads to higher than normal androgen levels and other hormonal imbalances. Those higher androgen levels are what the WHO links to irregular periods, ovulation problems, excess hair and acne.
Insulin resistance plays a part
The 2023 guideline describes insulin resistance as a pathophysiological factor in PCOS. A meta-analysis of 28 gold-standard clamp studies found insulin sensitivity was 27% lower in women with PCOS, independent of body mass index (BMI), and a higher BMI made that reduction larger. Read more: insulin resistance in women.
Genes run in families
A Dutch study of 1,332 identical twins and 1,873 non-identical twins and sisters of twins found a large influence of genetic factors on PCOS.
What are the signs of PCOD in females?
Signs of PCOS differ from person to person and can change over time. Possible symptoms include intermittent, unpredictable or absent periods, heavy or painful periods for some women, excess hair on the face or body, hair thinning, and acne or oily skin.
Period changes are often the first clue
PCOS is one of the most common causes of irregular periods. The 2023 guideline defines irregular cycles in adults, from three years after the first period until perimenopause, as cycles shorter than 21 days or longer than 35 days, or fewer than 8 cycles a year. Ovulation problems can still happen even when cycles arrive on time, and a progesterone blood test can confirm this.
Skin and hair changes
The guideline treats excess facial or body hair (hirsutism) on its own as a strong pointer to high androgens and PCOS in adults. Acne and female-pattern hair loss on their own, without excess hair, are relatively weak predictors of high androgens.
Weight and pregnancy
The WHO lists weight gain, especially around the belly, among the health conditions women with PCOS have an increased risk of developing. PCOS can start as early as adolescence but is most often diagnosed when women struggle to become pregnant. If you are planning a pregnancy, a gynaecologist can talk you through the options.
Read more: irregular periods, excess facial and body hair, hair thinning and weight gain.
How is PCOD diagnosed?
PCOS is diagnosed when at least two of three features of Rotterdam criteria are present, once other causes for the symptoms have been excluded: signs or blood levels of high androgens, irregular or absent periods, and polycystic ovaries on ultrasound.
These criteria build on the 2003 Rotterdam criteria, and the Rotterdam consensus concluded that no single feature, such as high androgens or polycystic ovaries alone, is enough for a diagnosis.
Cysts are not required
Some women with PCOS do not have polycystic ovaries at all. When irregular periods and high androgens are both present, the 2023 guideline says ultrasound or AMH are not needed to make the diagnosis.
Teenagers are assessed differently
In adolescents, the guideline requires both high androgens and ovulation problems, and does not recommend ultrasound or AMH because they are not specific enough at that age. The WHO notes that irregular periods can be normal around the first period and around perimenopause. If you are a teenager, it helps to see a gynaecologist together with a parent or guardian.
Getting a diagnosis can take time
In an international survey of 1,385 women with PCOS, about a third waited more than two years and 47.1% saw three or more health professionals before a diagnosis was made. An online gynaecologist consultation is one way to start that conversation.
What tests are done for PCOD?
Blood tests can show high androgen levels in women without visible excess hair or acne, or check ovulation when cycles seem normal. The 2023 guideline recommends total and free testosterone to assess high androgen levels, and the WHO says newly diagnosed women are recommended to have extra blood tests for insulin resistance and overall cardiovascular risk.
Ultrasound or AMH
The guideline allows a blood test for anti-Müllerian hormone (AMH) as an alternative to ultrasound, in adults only. It also recommends that AMH should not be used as a single test for diagnosis.
Checks for long-term health
Blood sugar status should be assessed at diagnosis in all adults and adolescents with PCOS, and all women with PCOS, whatever their age and BMI, should have a lipid profile at diagnosis. Insulin blood tests, on the other hand, are not recommended in routine care because available assays have limited clinical relevance.
Table 2. Tests a doctor may consider for PCOD, and why
| Test | Why a doctor may order it |
|---|---|
| Total and free testosterone | To assess high androgen levels |
| Pelvic ultrasound (adults) | To look for polycystic ovaries |
| AMH blood test (adults only) | An alternative to ultrasound, never used alone |
| Progesterone | To confirm whether ovulation is happening |
| Blood sugar (glycaemic status) | To check for diabetes risk at diagnosis |
| Lipid profile | To check cholesterol and triglycerides at diagnosis |
Tvarvi's PCOS Assessment personalises home tests through a short questionnaire, and a gynaecologist reviews your results.
What else can cause PCOD-like symptoms?
Common conditions checked in every woman
The Endocrine Society guideline lists thyroid disease, high prolactin and non-classic congenital adrenal hyperplasia (checked with a 17-hydroxyprogesterone blood test) as conditions to exclude in all women. Its table of other diagnoses also lists pregnancy, checked with a blood or urine hCG test, as a cause of absent periods, along with hypothalamic amenorrhoea, which is linked to low body weight and excessive exercise.
Rarer causes when androgen levels are very high
If androgen levels are markedly high, the 2023 guideline says doctors should consider other causes, including ovarian and adrenal growths, congenital adrenal hyperplasia, Cushing's syndrome and, after menopause, ovarian hyperthecosis. Read about PCOS blood tests with home sample collection.
Is PCOD dangerous?
PCOD deserves follow-up because women with PCOS have a higher risk of longer-term health problems, including insulin resistance, type 2 diabetes and obesity.
Blood sugar and the heart
A 2018 meta-analysis found women with PCOS had a higher prevalence of impaired glucose tolerance (odds ratio 3.26) and type 2 diabetes (odds ratio 2.87), and the increase in impaired glucose tolerance was about five-fold in studies from Asia. The 2023 guideline says women with PCOS should be considered at increased risk of cardiovascular disease, while noting the overall risk in pre-menopausal women is low.
The uterus lining
Infrequent periods may raise the risk of endometrial hyperplasia and endometrial cancer. A meta-analysis found women with PCOS had a higher risk of endometrial cancer (odds ratio 2.79), though its authors said this must be judged against the cancer's relatively low incidence in the general population. The 2023 guideline says routine screening is not recommended because the overall chance of endometrial cancer is low.
Sleep and liver health
Women with PCOS have a significantly higher prevalence of obstructive sleep apnoea than women without PCOS, independent of BMI; our article on PCOS and sleep problems explains the signs. In the 2024 national Indian study, 32.9% of women with PCOS had non-alcoholic fatty liver disease.
Is PCOD curable?
There is currently no cure for PCOS, but lifestyle changes and medicines can reduce symptoms and protect longer-term health. A StatPearls clinical reference describes it as a lifelong chronic metabolic condition, and the 2023 guideline says a PCOS diagnosis could be considered enduring or lifelong.
That makes early, steady care worthwhile: the WHO says seeking health care early to manage symptoms can help women protect their health during and beyond their reproductive years.
Care is built around your priorities
The WHO says treatment choices should be based on shared decision-making that takes your own values and preferences into account. The 2023 guideline also asks doctors to find out your key concerns and priorities.
How is PCOD treated?
Healthy eating and physical activity are important for all women with PCOS, even when they do not change weight, and a doctor may discuss medicines such as combined oral contraceptive pills or androgen receptor blockers.
Food
The 2023 guideline says there is no evidence to support any one type of diet over another, and any eating pattern in line with population healthy-eating guidelines will have health benefits. A nutritionist can personalise this around your routine and the food you already cook at home; Tvarvi's PCOS diet plan with a nutritionist page explains how that works.
Movement
The guideline recommends lifestyle intervention, meaning exercise alone or diet combined with exercise and behavioural strategies, for all women with PCOS to improve metabolic health. A Cochrane review found lifestyle changes may improve the free androgen index, a blood measure of androgens, although most included studies were low quality. The guideline also asks health professionals to be aware of weight stigma when they talk about lifestyle.
Medicines a doctor may discuss
The guideline says combined oral contraceptive pills could be recommended in adults for excess hair and irregular cycles, and their side effects and reasons not to use them need an individual discussion. It says metformin should be considered in adults with PCOS and a higher BMI for metabolic outcomes, including insulin resistance. Anti-androgens could be considered for excess hair, with effective contraception, if the response after at least six months of the pill or cosmetic treatment is not enough.
Can PCOD affect your mood and mental health?
A meta-analysis of 30 studies covering 3,050 women with PCOS found higher odds of moderate and severe depressive symptoms (odds ratio 4.18) and anxiety symptoms (odds ratio 6.55), and this link held independent of obesity. The WHO adds that social stigma around symptoms such as unwanted hair can affect relationships, work and mental health.
What the guideline asks doctors to do
The 2023 guideline asks health professionals to screen all adults and adolescents with PCOS for depression, and to consider eating disorders regardless of weight. Women diagnosed with depression, anxiety or eating disorders should be offered psychological therapy. You can talk to a counselling psychologist online, and our article on PCOS, mood swings, anxiety and depression has more detail.
What are the common myths about PCOD?
Several common beliefs about PCOD do not match the evidence.
Myth: you need cysts on your ovaries to have PCOD
Ovarian cysts are not required for a PCOS diagnosis, and the new name PMOS drops the word "cysts" altogether.
Myth: only women with higher weight get it
In the Mumbai study, 71.8% of young women diagnosed by Rotterdam criteria were not obese, and in the 2024 national study, obesity was present in 43.2% of women with PCOS. Our guide to lean PCOS explains how the condition shows up in women with lower weight.
Myth: PCOD is a milder stage that turns into PCOS
The 2023 guideline uses one set of criteria for one condition. For adolescents with some features who do not meet the criteria, the 2023 guideline suggests treating them as at "increased risk" and reassessing by 8 years after their first period. The 2024 Indian study called women with only one feature "pre-PCOS", and found they had similar metabolic changes.
How common is PCOD in India?
Estimates depend on which diagnostic criteria a study uses. The 2024 national study found PCOS in 7.2% of women by NIH 1990 criteria, 19.6% by Rotterdam 2003 criteria and 13.6% by AE-PCOS criteria.
That study recruited 9,824 women aged 18 to 40 across five zones of India between 2018 and 2022, and 8,993 were enrolled. A 2019 review in the Indian Journal of Medical Research reported Indian figures ranging from 3.7 to 22.5 per cent, depending on the population studied and the criteria used.
Table 3. PCOS estimates from Indian studies, by diagnostic criteria
| Study | Who was studied | Criteria | Estimate |
|---|---|---|---|
| Ganie et al., 2024 (national) | 8,993 women aged 18 to 40, five zones | NIH 1990 | 7.2% |
| Ganie et al., 2024 (national) | Same group | AE-PCOS | 13.6% |
| Ganie et al., 2024 (national) | Same group | Rotterdam 2003 | 19.6% |
| Joshi et al., 2014 (Mumbai) | 600 women aged 15 to 24 | Androgen Excess Society | 10.7% |
| Joshi et al., 2014 (Mumbai) | Same group | Rotterdam | 22.5% |
| Ganie et al., 2019 (review) | Indian studies combined | Various | 3.7 to 22.5% |
Source: Ganie et al., JAMA Netw Open, 2024; Joshi et al., Indian J Endocrinol Metab, 2014; Ganie et al., Indian J Med Res, 2019.
How India compares
When should you see a doctor for PCOD, and what should you ask?
See a gynaecologist if your periods are irregular or absent, or if excess hair, hair thinning or acne is worrying you, because the WHO says seeking care early can help protect your health.
Signs worth booking an appointment for
- Cycles longer than 35 days, shorter than 21 days, or fewer than 8 a year, from three years after your first period.
- Any single cycle longer than 90 days, from one year after your first period.
- Snoring along with waking unrefreshed, daytime sleepiness or fatigue, which the guideline says should prompt an assessment for sleep apnoea.
- Periods that have stopped, since pregnancy is one of the causes doctors check for.
Questions to ask your doctor
- Which of the diagnostic features do I have, and which other conditions have you ruled out?
- Which tests do I need now, and when should my blood sugar be rechecked? The guideline suggests reassessing it every one to three years, depending on your other risk factors.
- Which symptom should we focus on first, given what matters most to me?
- Should I be screened for depression or anxiety?
- If I am planning a pregnancy, what should I know?
If you want to organise your symptoms before the appointment, you can Take the PCOS questionnaire. It does not give a diagnosis.
Frequently asked questions
Can teenagers have PCOD?
Yes, PCOS can start as early as adolescence, and the guideline uses stricter criteria for adolescents. A teenager should see a gynaecologist together with a parent or guardian.
Does PCOD affect pregnancy?
Women with PCOS can be supported to become pregnant but generally have a higher risk of pregnancy complications that needs extra monitoring. If you are planning a pregnancy, a gynaecologist can talk you through the options.
Can I be tested for PCOD while taking the contraceptive pill?
The pill makes androgen levels hard to assess; if the test is essential, the guideline says the pill should be stopped for at least three months with other contraception used meanwhile. Always ask your doctor before stopping any medicine.
References
- Kalra S, Baruah MP, Saikia M. Trends in endocrine onomastics: The case of polycystic ovarian syndrome. Indian Journal of Endocrinology and Metabolism 17(4):545-547. 2013. DOI 10.4103/2230-8210.113719; PMID 23961468; PMC3743352. https://doi.org/10.4103/2230-8210.113719
- Teede HJ, Bahri Khomami M, Morman R, Laven JSE, Joham AE, Costello MF, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet 407(10545):2329-2339. 2026. DOI 10.1016/S0140-6736(26)00717-8; PMID 42119588. https://doi.org/10.1016/S0140-6736%2826%2900717-8
- World Health Organization. Polycystic ovary syndrome (fact sheet, 22 January 2026). World Health Organization. 2026. Not applicable (no DOI). https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome
- Shukla A, Rasquin LI, Anastasopoulou C. Polyendocrine Metabolic Ovarian Syndrome (StatPearls, updated 7 July 2025). StatPearls Publishing, NCBI Bookshelf. 2025. PMID 29083730; NBK459251. https://www.ncbi.nlm.nih.gov/books/NBK459251/
- Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian Journal of Endocrinology and Metabolism 18(3):317-324. 2014. DOI 10.4103/2230-8210.131162; PMID 24944925; PMC4056129. https://doi.org/10.4103/2230-8210.131162
- Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al.; International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction 38(9):1655-1679. 2023. DOI 10.1093/humrep/dead156; PMID 37580037; PMC10477934. https://doi.org/10.1093/humrep/dead156
- Ganie MA, Chowdhury S, Malhotra N, Sahay R, Bhattacharya PK, Agrawal S, et al.; PCOS Study Group. Prevalence, Phenotypes, and Comorbidities of Polycystic Ovary Syndrome Among Indian Women. JAMA Network Open 7(10):e2440583. 2024. DOI 10.1001/jamanetworkopen.2024.40583; PMID 39441596; PMC11581580. https://doi.org/10.1001/jamanetworkopen.2024.40583
- Teede HJ, Moran LJ, Morman R, Gibson M, Dokras A, Berry L, et al. Polycystic ovary syndrome perspectives from patients and health professionals on clinical features, current name, and renaming: a longitudinal international online survey. EClinicalMedicine 84:103287. 2025. DOI 10.1016/j.eclinm.2025.103287; PMID 40687737; PMC12273733. https://doi.org/10.1016/j.eclinm.2025.103287
- Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Human Reproduction 31(11):2619-2631. 2016. DOI 10.1093/humrep/dew243; PMID 27907900. https://doi.org/10.1093/humrep/dew243
- Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. Journal of Clinical Endocrinology and Metabolism 91(6):2100-2104. 2006. DOI 10.1210/jc.2005-1494; PMID 16219714. https://doi.org/10.1210/jc.2005-1494
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 19(1):41-47. 2004. DOI 10.1093/humrep/deh098; PMID 14688154. https://doi.org/10.1093/humrep/deh098
- Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism 102(2):604-612. 2017. DOI 10.1210/jc.2016-2963; PMID 27906550; PMC6283441. https://doi.org/10.1210/jc.2016-2963
- Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 98(12):4565-4592. 2013. DOI 10.1210/jc.2013-2350; PMID 24151290; PMC5399492. https://doi.org/10.1210/jc.2013-2350
- Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update 24(4):455-467. 2018. DOI 10.1093/humupd/dmy007; PMID 29590375. https://doi.org/10.1093/humupd/dmy007
- Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 20(5):748-758. 2014. DOI 10.1093/humupd/dmu012; PMID 24688118; PMC4326303. https://doi.org/10.1093/humupd/dmu012
- Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 3:CD007506. 2019. DOI 10.1002/14651858.CD007506.pub4; PMID 30921477; PMC6438659. https://doi.org/10.1002/14651858.CD007506.pub4
- Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction 32(5):1075-1091. 2017. DOI 10.1093/humrep/dex044; PMID 28333286. https://doi.org/10.1093/humrep/dex044
- Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian Journal of Medical Research 150(4):333-344. 2019. DOI 10.4103/ijmr.IJMR_1937_17; PMID 31823915; PMC6902362. https://doi.org/10.4103/ijmr.IJMR_1937_17
Disclaimer
This article is general information and is not medical advice, diagnosis or treatment. Please speak to a registered doctor about your own symptoms before starting, stopping or changing any medicine. If you are in distress or having thoughts of self-harm, call Tele MANAS, the Government of India's free mental health helpline, on 14416 (https://telemanas.mohfw.gov.in/), or go to your nearest emergency department.
PCOS Assessment
₹1,490
A gynaecologist consult and the tests your symptoms need, collected at home.





